These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 16211044)

  • 21. Open-minded to open innovation and precompetitive collaboration.
    Wagner JA
    Clin Pharmacol Ther; 2010 May; 87(5):511-5. PubMed ID: 20407451
    [No Abstract]   [Full Text] [Related]  

  • 22. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 23. Indian generics companies go on spending spree.
    Jayaraman KS
    Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583
    [No Abstract]   [Full Text] [Related]  

  • 24. Showcasing bioscience in Rhode Island.
    Spero D
    R I Med J (2013); 2013 Feb; 96(2):15. PubMed ID: 23641419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What mergers can do for you.
    Acharya A
    Nat Biotechnol; 2011 Jun; 29(6):477-9. PubMed ID: 21796820
    [No Abstract]   [Full Text] [Related]  

  • 26. Follow-on biologics: data exclusivity and the balance between innovation and competition.
    Grabowski H
    Nat Rev Drug Discov; 2008 Jun; 7(6):479-88. PubMed ID: 18469828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 28. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
    Stipp D
    Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
    [No Abstract]   [Full Text] [Related]  

  • 29. Setbacks for blood substitute companies.
    Niiler E
    Nat Biotechnol; 2002 Oct; 20(10):962-3. PubMed ID: 12355103
    [No Abstract]   [Full Text] [Related]  

  • 30. Any diamonds in the diagnostic coal?
    Jacobs T
    Nat Biotechnol; 2006 Aug; 24(8):930. PubMed ID: 16900133
    [No Abstract]   [Full Text] [Related]  

  • 31. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 32. A rollercoaster ride.
    Jacobs T
    Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
    [No Abstract]   [Full Text] [Related]  

  • 33. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 34. The further evolution of biotech.
    Nagle T; Berg C; Nassr R; Pang K
    Nat Rev Drug Discov; 2003 Jan; 2(1):75-9. PubMed ID: 12509762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 36. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

  • 37. Merck wipes Serono off Swiss biotech map.
    Urquhart L
    Nat Biotechnol; 2006 Nov; 24(11):1303. PubMed ID: 17093457
    [No Abstract]   [Full Text] [Related]  

  • 38. This Dutchman is flying.
    Watson N
    Fortune; 2003 Jun; 147(13):89-90. PubMed ID: 12827720
    [No Abstract]   [Full Text] [Related]  

  • 39. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First inhalable insulin approved.
    Katsnelson A
    Nat Biotechnol; 2006 Apr; 24(4):369-70. PubMed ID: 16601705
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.